Gene expression profiling predicts response to temozolomide in malignant gliomas

International Journal of Oncology

Volumn 36, Issue 6, 2010, Pages 1367-1377

  Yoshino, Atsuo ^a   Ogino, Akiyoshi ^a   Yachi, Kazunari ^a   Ohta, Takashi ^a   Fukushima, Takao ^a   Watanabe, Takao ^a   Katayama, Yoichi ^a   Okamoto, Yutaka ^b   Naruse, Norio ^c   Sano, Emiko ^d   Tsumoto, Kouhei ^d  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Toray Medical Company   (Japan)

^c Proteios Research Inc   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chemotherapy; Malignant glioma; Methylation; MGMT; Temozolomide

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLTRANSFERASE; MIDKINE; PROTEIN LEVO ISOASPARTATE O METHYLTRANSFERASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHROMOSOMAL LOCALIZATION; DNA METHYLATION; DNA MICROARRAY; DOWN REGULATION; DRUG SENSITIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; UPREGULATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GLIOMA; HUMANS; INHIBITORY CONCENTRATION 50; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 77951580527     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000621     Document Type: Article

References (48)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. (Pubitemid 40349501)
2. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
3. Friedman HS, Kerby T and Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res 5: 2585-2597, 2000.
4. Maxwell JA, Johnson SP, McLendon RE, et al: Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 14: 4859-4868, 2008.
5. Augustine CK, Yoo JS, Potti A, et al: Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 15: 502-510, 2009.
6. Auger N, Thillet J, Wanherdrick K, et al: Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. Mol Cancer Ther 5: 2182-2192, 2006. (Pubitemid 44530454)
7. Kaina B and Christmann M: DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther 40: 354-367, 2002. (Pubitemid 34846106)
8. 6-alkylating agents in human glioblastoma. J Clin Oncol 24: 274-287, 2006.
9. Staunton JE, Slonim DK, Coller HA, et al: Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98: 10787-10792, 2001.
10. Potti A, Dressman HK, Bild A, et al: Genomic signatures to guide the use of chemotherapeutics. Nat Med 12: 1294-1300, 2006. (Pubitemid 44706932)
11. Takahashi Y, Nagata T, Ishii Y, Ikarashi M, Ishikawa K and Asai S: Up-regulation of vitamin D3 up-regulated protein 1 gene in response to 5-fluorouracil in colon carcinoma SW620. Oncol Rep 9: 75-79, 2002.
12. Blalock EM, Chen KC, Sharrow K, Herman JP, Porter NM, Foster TC and Landfield PW: Gene microarray in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J Neurosci 23: 3807-3819, 2003. (Pubitemid 36958487)
13. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119-6129, 1990.
14. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51: 167-223, 1995.
15. Gerson SL: Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20: 2388-2399, 2002.
16. Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG island. Proc Natl Acad Sci USA 93: 9821-9826, 1996. (Pubitemid 26296693)
17. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59: 793-797, 1999.
18. 6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 13: 176-184, 2003.
19. Watanabe T, Katayama Y, Ogino A, Ohta T, Yoshino A and Fukushima T: Preliminary individualized chemotherapy for malignant astrocytoma based on O6-methylguanine-deoxyribonucleic acid methyltransferase methylation analysis. Neurol Med Chir 46: 387-394, 2006.
20. 6-methylguanine-DNA methyltransferase gene expression in gliomas by quantitative real-time RT-PCR and clinical response to nitrosoureas. Int J Cancer 103: 67-72, 2003.
21. 6-methylguanine-DNA methyltransferase gene messenger RNA in gliomas by means of real-time RT-PCR and clinical response to nitrosoureas. Cell Mol Neurobiol 25: 1067-1071, 2005.
22. Yachi K, Watanabe T, Ohta T, et al: Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas. Int J Oncol 33: 469-475, 2008.
23. Yoshino A, Ogino A, Yachi K, et al: Effect of INF-ß on human glioma cell lines with temozolomide resistance. Int J Oncol 35: 139-148, 2008.
24. Maglott D, Ostell J, Pruitt KD and Tatusova T: Entrez gene: gene-centered information at NCBI. Nucleic Acids Res 35: D26-D31, 2007. (Pubitemid 46056164)
25. Davoust N, Wion D, Chevalier G, Garabedian M, Brachet P and Couez D: Vitamin D receptor stable transfection restores the susceptibility to 1,25-dihydroxyvitamin D3 cytotoxicity in a rat glioma resistant clone. J Neurosci Res 52: 210-219, 1998. (Pubitemid 28186165)
26. Diesel B, Radermacher J, Bureik M, et al: Vitamin D3 metabolism in human glioblastoma multiforme: functionality of CYP27B1 splice variants, metabolism of calcidiol, and effect of calcitriol. Clin Cancer Res 11: 5370-5380, 2005. (Pubitemid 41060810)
27. Lapointe M, Lanthier J, Moumdjian R, Régina A and Desrosiers RR: Expression and activity of L-isoaspartyl methyltransferase decrease in stage progression of human astrocytic tumors. Brain Res Mol Brain Res 135: 93-103, 2005. (Pubitemid 40602402)
28. Mirkin BL, Clark S, Zheng X, Chu F, White BD, Greene M and Rebbaa A: Identification of midkine as a mediator for intercellular transfer of drug resistance. Oncogene 24: 4965-4974, 2005. (Pubitemid 41129100)
29. Mashima T, Sato S, Sugimoto Y, Tsuruo T and Seimiya H: Promotion of glioma cell survival by acyl-CoA synthetase 5 under extracellular acidosis conditions. Oncogene 28: 9-19, 2009.
30. Scherf U, Ross DT, Waltham M, et al: A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 227-235, 2000. (Pubitemid 30132189)
31. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S and Sobol RW: The role of base excision repair and the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 65: 6394-6400, 2005. (Pubitemid 40994427)
32. Friedman HS, Johnson SP, Dong O, et al: Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 57: 2933-2936, 1997.
33. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
34. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al: CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10: 4933-4938, 2004. (Pubitemid 39099766)
35. Watanabe T, Katayama Y, Komine C, Yoshino A, Ogino A, Ohta T and Fukushima T: O6-Methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationship with clinical course. Int J Cancer 113: 581-587, 2005. (Pubitemid 40038734)
36. Drablos F, Feyzi E, Aas PA, et al: Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair (Amst) 3: 1389-1407, 2004. (Pubitemid 39221738)
37. Györffy B, Surowiak P, Kiesslich O, Schäfer R, Dietel M and Lage H: Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118: 1699-1712, 2006. (Pubitemid 43376433)
38. Zhang JT: Use of array to investigate the contribution of ATP-binding cassette transporters to drug resistance in cancer chemotherapy and prediction of chemosensitivity. Cell Res 17: 311-323, 2007.
39. Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K and Gallo JM: Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol 63: 1219-1228, 2002. (Pubitemid 34311991)
40. Kanzawa T, Bedwell J, Kondo Y, Kondo S and Germano IM: Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 99: 1047-1052, 2003. (Pubitemid 44717401)
41. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M and Yoshida J: IFN-ß down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 65: 7573-7579, 2005.
42. 6-benzylguanine in adults with recurrent, temozolomide- resistant malignant glioma. J Clin Oncol 10: 1262-1267, 2009.
43. Wang CY, Cusack JC Jr, Liu R, et al: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417, 1999. (Pubitemid 29180579)
44. Nakanishi C and Toi M: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309, 2005. (Pubitemid 40488635)
45. Weaver KD, Yeyeodu S, Cusack JC, Baldwin AS Jr and Ewend MG: Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 61: 187-196, 2003. (Pubitemid 36342295)
46. Murat A, Migliavacca E, Gorlia T, et al: Stem cell-related 'self-renewal' signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26: 3015-3024, 2008.
47. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 1375-1382, 2002. (Pubitemid 34177445)
48. Bacolod MD, Lin SM, Johnson SP, Bullock NS, Colvin M, Bigner DD and Friedman HS: The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. Curr Cancer Drug Targets 8: 172-179, 2008. (Pubitemid 351666854)